Trevena. has filed a patent for compounds acting as beta-arrestin effectors to treat ARDS, thrombosis, and platelet aggregation in subjects with viral infections like coronavirus. The method involves administering specific peptides or peptide mimetics with defined sequences and characteristics. GlobalData’s report on Trevena gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Trevena, Telomerase reverse transcriptase screening was a key innovation area identified from patents. Trevena's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20240025949A1) discloses a method for treating acute respiratory distress syndrome (ARDS) in a subject by administering a specific peptide or peptide mimetic. The peptide sequence includes a combination of amino acids such as sarcosine, L-arginine, L-isoleucine, and L-histidine, among others. The peptide or peptide mimetic must maintain a specific sequence structure with spacers of 1-3 amino acids inserted between them, and the total length of the peptide should be between 6 and 25 amino acids. Additionally, the patent claims that the peptide can be cyclic, dimerized, or trimerized for enhanced efficacy.
Furthermore, the patent also covers methods for reducing D-Dimer levels in circulation in subjects with ARDS or viral infections by administering a different peptide or peptide mimetic. This peptide sequence includes amino acids such as Sar, Arg, Val, L-tyrosine, and L-isoleucine, among others. The patent specifies that the peptide must maintain a specific sequence structure with spacers of 1-3 amino acids inserted between them, and the total length of the peptide should be between 8 and 25 amino acids. The patent also claims that the peptide can be at least 70% identical to the described sequences for effective reduction of D-Dimer levels. Additionally, the patent covers methods for reducing the length of hospital stay in subjects with ARDS or viral infections by administering the same peptide or peptide mimetic, particularly in cases of coronavirus infections.
To know more about GlobalData’s detailed insights on Trevena, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
